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Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA 
damage sensors that are most active during S-phase of the cell 
cycle and that have wider-reaching roles in DNA repair than 
originally described. BRCA1 and BRCA2 (Breast Cancer) proteins 
are involved in homologous recombination repair (HRR), which 
requires a homologous chromosome or sister chromatid as a 
template to faithfully repair DNA double-strand breaks. The 
small-molecule NAD+ mimetics, olaparib, niraparib, rucaparib, 
veliparib, and talazoparib, inhibit the catalytic activity of PARP-1 
and PARP-2 and are currently being studied in later-stage clinical 
trials. PARP inhibitor clinical trials have predominantly focused 
on patients with breast and ovarian cancer with deleterious 
germline BRCA1 and BRCA2 mutations (gBRCA1/2+) but are now 
expanding to include cancers with known, suspected, or more-
likely-than-not defects in homologous recombination repair. In 
ovarian cancer, this group also includes women whose cancers 
are responsive to platinum therapy. Olaparib was FDA-approved 
in January 2018 for the treatment of gBRCA1/2+ metastatic breast 
cancers. gBRCA1+ predisposes women to develop triple-negative 
breast cancers, while women with gBRCA2+ tend to develop 
hormone-receptor-positive, human epidermal growth factor 
receptor 2 negative breast cancers. Although PARP inhibitor 
monotherapy strategies seem most effective in cancers with 
homologous recombination repair defects, combination 
strategies may allow expansion into a wider range of cancers. By 
interfering with DNA repair, PARP inhibitors essentially sensitize 
cells to DNA-damaging chemotherapies and radiation therapy. 
Certainly, one could also consider expanding the utility of PARP 
inhibitors beyond gBRCA1/2+ cancers by causing DNA damage 
with cytotoxic agents in the presence of a DNA repair inhibitor. 
Unfortunately, in numerous phase I clinical trials utilizing a 
combination of cytotoxic chemotherapy at standard doses with 
dose-escalation of PARP inhibitors, there has generally been 
failure to reach monotherapy dosages of PARP inhibitors due 
to myelosuppressive toxicities. Strategies utilizing angiogenesis 
inhibitors and immune checkpoint inhibitors are generally not 
hindered by additive toxicities, though the utility of combining 
PARP inhibitors with treatments that have not been particularly 
effective in breast cancers somewhat tempers enthusiasm. 
Finally, there are combination strategies that may serve to 
mitigate resistance to PARP inhibitors, namely, upregulation of 
the intracellular PhosphoInositide-3-kinase, AK thymoma (protein 
kinase B), mechanistic target of rapamycin (PI3K–AKT–mTOR) 
pathway, or perhaps are more simply meant to interfere with a 
cell growth pathway heavily implicated in breast cancers while 
administering relatively well-tolerated PARP inhibitor therapy.
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Introduction
In the care of oncology patients, poly-ADP-ribose polymerase 
(PARP) inhibitors are best known as a semitargeted treatment 
for BRCA1- and BRCA2-associated ovarian and breast cancers, 
but a broader understanding of PARP biology has spurred 
interest in expanding their clinical utility (see Figure 1). Using 
NAD+ as a substrate, PARP enzymes catalyze the addition of 
linear and branching chains of ADP-ribose to aspartic acid, 
glutamic acid, and/or lysine amino acids on acceptor proteins 
in a process termed poly-ADP-ribose-ylation (‘PARylation’).1 
Seventeen PARP enzymes have been discovered, with their 
functionalities primarily determined by their target-binding 
domains, cellular compartment localization signals, and tertiary 
structures.1,2 PARP-1 and PARP-2 localize to the nucleus and 
undergo conformational changes to become catalytically 
activated upon binding to exposed DNA. They effectively act as 
sensors of DNA damage – including single-strand and double-
strand DNA breaks, DNA supercoils, DNA crosslinks, and stalled 
replication forks – and facilitate DNA repair processes at the 
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site of damage.3 PARP-1 self-PARylates its automodification 
domain to release itself from DNA, a process that is inhibited in 
the presence of PARP inhibitors (PARPi) and has been termed 
‘PARP-trapping.’2,4,5
PARP-1 and PARP-2 are the primary targets of PARPi in 
clinical development due to their roles in the repair of DNA, 
but the understanding of PARP-1’s role in DNA repair has 
shifted over time. PARP-1 was originally described as part 
of the base excision repair (BER) pathway based on genetic 
studies, but PARP-1 and PARylation are now known to have 
much wider-reaching roles in all major DNA repair pathways. 
PARP-1 has been implicated in chromatin relaxation by 
histone modification, recruitment of repair proteins to the site 
of DNA damage, inhibition of transcription through PARylation 
of Ribonucleic acid (RNA) polymerases I and II, cell cycle arrest, 
and apoptosis.2,6–8 During apoptosis, caspase-mediated 
cleavage of PARP-1 releases the N-terminal nuclear localization 
signal and DNA-binding domains from the C-terminal catalytic 
and auto-PARylation domains, uncoupling DNA repair and 
DNA binding (Figure 2).2,3,9 The N-terminal fragment of 
‘cleaved PARP’ binds DNA in a natural form of PARP-trapping 
to prevent DNA repair, replication, and transcription in a 
dying cell.9 
PARPi are molecular mimics of nicotinamide that compete 
with NAD+ at the catalytic site of PARP enzymes and thus 
prevent PARylation. Their specificity for one or more of the 
PARP enzymes varies, as does their potency.10–12 By interfering 
with its ability to PARylate itself but not its ability to bind 
DNA, PARP-1 inhibitors also result in PARP-trapping.4,5 In 
addition to interfering with DNA repair, transcription, and 
replication, PARP-trapping can itself cause lethal DNA 
double-strand breaks during S-phase by collapse of stalled 
replication forks.13 The most well-represented PARPi in 
clinical trials include olaparib, veliparib, niraparib, rucaparib, 
and talazoparib.14–18 Although iniparib was found to inhibit 
PARP-1 function in vitro and was tested in clinical trials, it 
was eventually found to bind to PARP-1’s zinc-finger domain 
rather than the catalytic domain and is no longer considered 
to be a PARP inhibitor for the purposes of clinical trial 
research.19,20
Early clinical trials were designed to use PARPi in patients  
with germline BRCA1 or BRCA2 mutations with breast 
and ovarian cancers deficient in DNA repair by HRR due 
to acquired loss of BRCA1/2 heterozygosity.21–23 With an 
understanding of PARP as a BER enzyme, the PARPi were 
thought to contribute to a type of ‘synthetic lethality’ by 
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PARP-1 and PARP-2 recognize DNA damage, including single-strand and double-strand DNA breaks, DNA crosslinks, supercoils, 
and stalled replication forks. Upon binding to DNA, PARP-1 and PARP-2 become catalytically active, utilizing nicotinamide as 
a substrate to add ADP-ribose chains to target proteins in a process termed ‘PARylation.’ PARylation of histones H2B and H1 
relaxes the chromatin to allow access to DNA for repair, the G2/M checkpoint is activated to allow time to repair DNA, DNA 
repair proteins are recruited to the site of damage, and transcription is temporarily halted via PARylation of RNA Pol I and 
RNA Pol II. PARP-1 also has roles to play in cell death if DNA cannot be repaired, both as an active participant in apoptosis and 
indirectly by draining the cell of its nicotinamide resources, which is necessary for normal cell respiration. 
ATM, Ataxia telangiectasia mutated serine/threonine kinase; dsDNA, double-stranded DNA; NAD+, nicotinamide; PARP-1,  
poly-ADP-ribosyl polymerase 1; PARylation, poly(ADP-ribose)ylation; ssDNA, single-stranded DNA.
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PARP inhibitor monotherapy
Olaparib, rucaparib, and niraparib are approved for use in 
ovarian cancer as monotherapy.104–110 Efficacy data for PARP 
inhibitor monotherapy in breast cancer patients primarily 
come from early stage clinical trials. However, two phase III 
studies evaluating single agent PARP inhibition (olaparib and 
talazoparib) in advanced breast cancer have recently been 
reported, resulting in the first regulatory approval of a PARP 
inhibitor for breast cancer. The results of monotherapy studies 
are reviewed later.
Olaparib
In 2009, Fong et al. published the results of a phase I clinical 
trial (NCT00516373) of olaparib in patients with advanced 
solid tumors followed by an expansion cohort enriched for 
gBRCA1/2+ patients with ovarian and breast cancers.27 One 
of the nine breast cancer patients – gBRCA2+ with extensive 
pulmonary metastases and progression on anthracycline-based 
chemotherapy – had a complete response (CR) that lasted 
over 60 months. An additional 3/9 breast cancer patients, one 
gBRCA2+ and two BRCA wild-type (BRCA-wt), had stable disease 
(SD) for 4 months or more. 
The nature of phase I clinical trials with cytotoxic therapies is 
to dose-escalate to a maximum tolerated dose (MTD) based 
on dose-limiting toxicities (DLTs) to establish a recommended 
phase II dose (RP2D). The minimal effective dose is not usually 
determined, though in clinical practice cytotoxic therapies 
are often dose-reduced from standard doses according to an 
which inhibition of two DNA repair pathways contributes 
to preferential cell kill in HRR-deficient cancerous cells 
over normal cells. As knowledge of PARP-1’s roles and 
the mechanisms by which PARPi exert their efficacy has 
expanded, an updated basic science understanding also 
considers PARPi as 1) interfering with the identification of 
DNA damage and multiple types of repair, 2) predominantly 
exerting their effects during S-phase when dependence  
on PARP-1 and PARP-2 is highest, DNA is exposed for 
replication, and HRR is preferred over nonhomologous  
end-joining (NHEJ) for repair of DNA double-strand breaks, 
and3 likely to be strongly dose-dependent if PARP-trapping  
is a clinically relevant in vivo mechanism.1,4–6,8 These concepts 
drive some of the PARPi combination trials, as is most evident 
in the plethora of combination clinical trials for ovarian 
cancer.24 
Current PARPi clinical trials registered with the National 
Institutes of Health’s United States National Library of Medicine 
in ClinicalTrials.gov which include patients with breast 
cancer are listed in Table 1, which is headed by monotherapy 
trials followed by combination trials, organized by type of 
combination (e.g. PARPi + chemotherapy) and clinical trial 
phase from I to III within each category, and includes trial 
characteristics, patient population (with gBRCA1/2 bolded if 
a requirement for a particular trial), trial interventions with 
the PARPi bolded for easy reference, and outcome measures. 
Search terms were ‘breast cancer’ and ‘PARP.’ Data for individual 
trials were garnered using the Google and Google Scholar 
search engines to identify published manuscripts and oncology 
conference abstracts.
Figure 2. PARP-1 protein domains.
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PARP-1 and PARP-2’s protein domains include zing finger DNA-binding domains and a nuclear localization signal on the 
N-terminus. Their catalytic domain with NAD+ binding site is located on the C-terminus. Unique to PARP-1 is a BRCT domain 
upon which PARP-1 auto-PARylates itself, undergoing a conformational change that frees the protein from its DNA target, and 
a caspase cleavage site that separates the DNA-binding domains from PARP-1’s DNA repair functions.2,3
BRCT, BRCA1 C-terminus domain; NAD+, Nicotinamide adenine dinucleotide; NLS, nuclear localization signal; PARP-1,  
poly-ADP-ribosyl polymerase 1; PARylation, poly(ADP-ribose)ylation; Zn, zinc finger DNA-binding domains.
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7.4 months based on blinded-independent central review (BICR) 
compared to the chemotherapy arm (n=97) with mPFS of 4.2 
months (95% CI: 2.8–4.3 months) by investigator analysis and 4.2 
months (95% CI: 2.8–4.3 months) on BICR (hazard ratio [HR] 0.58, 
95% CI: 0.43–0.80, p<0.001). Of the patients with measurable 
disease, 59.9% (100/167) on olaparib had an objective response 
compared to 28.8% (19/66) of the patients given chemotherapy. 
OS was not significantly different between the arms at 19.3 
months in the PARP inhibitor arm and 19.6 months in the 
chemotherapy arm (HR 0.90, 95% CI: 0.63–1.29, p=0.57). The rate 
of grade 3 and 4 adverse events was lower in the olaparib arm at 
36.6% compared to 50.5% in the chemotherapy arm. The most 
common grade 3/4 toxicities were anemia (16.1%), neutropenia 
(9.3%), and leukopenia (3.4%). Low-grade gastrointestinal side-
effects were also common, including nausea (58.0%), vomiting 
(29.8%), and diarrhea (grade 1/2 20.0%, grade 3/4 0.5%). 
Olaparib was FDA-approved in January 2018 for gBRCA1/2+ 
HER2– breast cancers in the metastatic setting.
Talazoparib
In phase I/II trial NCT01286987 with talazoparib, 50% (7/14) of 
gBRCA1/2+ breast cancer patients had an objective response 
at the 1.0 mg p.o. daily dose.35 The phase II ABRAZO trial 
(NCT02034916) investigated talazoparib in patients with 
gBRCA1/2+ locally advanced or metastatic breast cancers with 
or without prior exposure to platinum agents.46 Those enrolled 
in the platinum-exposed arm were required to have had a 
documented PR or CR and could not have had progression of 
their disease on a platinum agent. Those who had not been 
exposed to platinum were required to have had two or more 
nonplatinum regimens in the metastatic setting. The primary 
outcome measure was ORR with CBR, PFS, and OS among the 
secondary outcome measures. Response rates to talazoparib 
were higher in patients who had not had prior platinum 
exposure, suggesting some degree of cross-resistance. The ORR 
was 20.8% (95% CI: 10.47–34.99) with a CBR of 27.1% (95% CI: 
15.28–41.85) in the platinum-exposed cohort (n=48). In those 
without prior platinum exposure (n=35), the ORR was 37.1% 
(95% CI: 21.49–55.08) with CBR 45.7% (95% CI: 28.83–63.35). 
mPFS was 4.0 months (95% CI: 2.8–5.4 months) with a median 
overall survival (mOS) of 11.8 months (95% CI: 8.8–15.0) in those 
with prior platinum exposure (n=49), but 5.6 months (95% CI: 
5.5–7.8 months) with mOS 16.5 months in the nonplatinum-
exposed arm (n=35). As with all PARPi, myelosuppression was 
the predominant toxicity. 
EMBRACA (NCT01945775) is a recently reported phase III study 
comparing talazoparib, 1 mg p.o. daily.46,49,53,111 to physician’s 
choice chemotherapy (eribulin, vinorelbine, capecitabine, or 
gemcitabine) in patients with advanced breast cancer and 
germline BRCA1 or BRCA2 mutations.112 Patients were randomly 
assigned in a 2:1 ratio to talazoparib (n=287) or chemotherapy 
(n=144). The primary endpoint was PFS (assessed by BICR) 
with secondary endpoints being safety, OS, ORR, CBR at 
24 weeks, and quality of life measurements. mPFS was 8.6 
individual patient’s toxicities. It could be argued that PARP 
inhibitors are a novel cytotoxic therapy, as they do essentially 
perpetuate DNA damage and have myelosuppression as the 
DLT. Olaparib was originally FDA-approved at a dosage of 
400 mg by mouth twice daily, which required patients to take 
eight 50 mg capsules twice a day. The phase II trial ICEBERG 1 
(NCT00494234) investigated dosage levels of 100 mg by mouth 
twice daily (n=27) compared with 400 mg by mouth twice daily 
(n=27) in women with gBRCA1/2 mutations with advanced 
breast cancers after a minimum of one cytotoxic regimen in 
the metastatic setting. The 100 mg dosage was grossly inferior 
in terms of median progression free survival (mPFS), overall 
response rate (ORR), and clinical benefit rate (CBR).36 Women in 
the olaparib, 100 mg by mouth twice daily (p.o. b.i.d.), arm had 
a mPFS of 122 days (n=24) compared with 193 days (n=26), ORR 
of 22% (n=27; 95% CI: 11–41) compared with 41% (n=27; 95% CI: 
25–59), and CBR 62.5% (n=24; 95% CI: 42.7–78.8) compared with 
84.6% (n=26; 95% CI: 66.5–93.9).37 
Disappointingly, there were no confirmed partial or CRs in 
the phase II trial NCT00679783 with olaparib, 400 mg p.o. 
b.i.d., in patients with advanced gBRCA1/2+ breast cancer or 
triple-negative breast cancer (TNBC) (n=26 with 4 gBRCA1+, 
6 gBRCA2+, 16 BRCA-wt).38 Five of the ten gBRCA1/2+ breast 
patients did actually have decrease in the size of target lesions 
by >30%, but three were not confirmed at the next follow up 
visit and two were taken off study for progression of nontarget 
lesions or new lesions. Of the 23 breast cancer patients 
evaluable for response, almost 1/3 had SD at 8 weeks, including 
2 of 3 gBRCA1+, 3 of 5 gBRCA2+, and 2 of 14 BRCA-wt patients.39 
A tablet formulation of olaparib was developed in part 
to reduce the 16-capsule/day pill burden on patients. 
Pharmacokinetic parameters for capsule versus tablet 
formulations were compared in the first stage of phase I trial 
NCT00777582 with the determination that the olaparib, 300 
mg p.o. b.i.d., tablet formulation matched or exceeded drug 
exposure at steady state compared to the 400 mg p.o. b.i.d. 
capsule form.28 In the expansion phase, patients with advanced 
solid tumors refractory to standard therapies were randomly 
assigned to receive olaparib, 400 mg p.o. b.i.d., in capsule 
formulation, 400 mg p.o. b.i.d. in tablet form, or 300 mg p.o. 
b.i.d. in tablet form. Efficacy was similar in all three arms, but 
the 300 mg p.o. b.i.d. tablet dosing was more tolerable. In fact, 
almost 2/3 of patients taking 400 mg p.o. b.i.d. tablets required 
dose reduction to 300 mg p.o. b.i.d. The olaparib monotherapy 
dose for phase II and III clinical trials thereafter was set at 
300 mg p.o. b.i.d. tabs, which reduced the pill burden from 16 
capsules a day to four tablets a day.28
The phase III OlympiAD trial randomized patients with 
gBRCA1/2+ metastatic breast cancer to olaparib, 300 mg 
p.o. b.i.d., compared with physician’s choice of capecitabine, 
vinorelbine, or eribulin.51 The primary outcome measure 
was mPFS with ORR and overall survival (OS) as secondary 
endpoints. mPFS in the olaparib arm (n=205) was 7.0 months 
(95% CI: 5.7–8.3 months) based on investigator analysis and  
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the use of standard dosages of chemotherapy over maximum 
doses of PARP inhibitor. In combination with myelosuppressive 
chemotherapies with efficacy in ovarian and breast cancers 
with HRR defects, namely, platinum agents in combination 
with taxane therapy, the RP2Ds of PARPi are a fraction of that 
required for efficacy as a monotherapy. In the phase II adjuvant 
BRE09-146 trial (NCT01074970), patients with gBRCA1/2+ breast 
cancers or TNBC were randomized to cisplatin, 75 mg/m2 on 
day 1 of a 21-day cycle +/– rucaparib, 30 mg intravenously (IV) 
on days 1–3, after completion of neoadjuvant chemotherapy 
and surgery with curative intent. For reference, rucaparib, 24 
mg IV, is approximately equivalent to 57 mg by mouth, and 
the monotherapy dose of rucaparib is 600 mg by mouth twice 
a day.122 At 2 years, the disease-free survival was 58.3% in the 
cisplatin arm compared with 63.1% in the cisplatin + rucaparib 
arm (p=0.43).126,127 It is not currently clear if maximizing the 
PARPi dose at the expense of the cytotoxic chemotherapy is a 
more viable therapeutic strategy, but the results of the phase III 
BrighTNess trial (discussed later) suggests that using a grossly 
subtherapeutic dose of PARPi in combination with standard 
dosages of chemotherapy does not significantly improve 
clinical outcomes.128
Strategies to mitigate the myelosuppressive effects of PARPi 
have mirrored strategies utilized for myelosuppressive 
cytotoxic chemotherapies, including intermittent dosing 
schedules and support with granulocyte colony stimulating 
factors (G-CSF) such as filgrastim. Phase I/II clinical trial 
NCT00707707 was amended to include an algorithm for 
filgrastim rescue and subsequent prophylaxis for women with 
metastatic TNBC being treated with olaparib, 200 mg p.o. 
b.i.d. continuously, in combination with paclitaxel, 90 mg/m2 
weekly × 3 weeks of a 28-day cycle, after 7/9 women in cohort 
1 developed neutropenia (4/9 grade 3 or 4) with 8/9 requiring 
dose delay or reduction of paclitaxel.73 After implementation 
of neutropenia management with G-CSF, cohort 2 (n=10) fared 
better, with 4/10 developing neutropenia (2/10 grade 3 or 4) 
and fewer paclitaxel dose reductions.
In the ongoing phase II neoadjuvant I-SPY 2 trial 
(NCT01042379), breast cancer patients with operable stage II–III 
or stage IV with solely supraclavicular lymph node involvement 
(‘regional stage IV’) and tumors ≥ 2.5 cm are randomized 
to one of many experimental arms with a standard-of-care 
control arm of paclitaxel, 80 mg/m2 weekly × 12 weeks (T), 
followed by doxorubicin + cyclophosphamide (AC) ×4 cycles.77 
The primary outcome measure is probability of pathologic 
complete response (pCR) over standard neoadjuvant therapy. 
I-SPY 2 included an experimental arm with PARP inhibitor 
veliparib, which was dosed at 50 mg p.o. b.i.d. continuously in 
conjunction with paclitaxel + carboplatin AUC6 on day 1 of a 
21-day cycle (TCV) and followed by AC ×4 cycles. The estimated 
pCR rate in TNBC of TCV ⇒ AC (n=72) was estimated to be 51% 
(95% Bayesian probability interval 36–66%) compared to 26% 
in the T ⇒ AC arm (n=44) (95% Bayesian probability interval 
9–43%). The predicted probability of success of TCV ⇒ AC in 
TNBC patients in a phase III trial was estimated to be 88%. 
months in the talazoparib arm compared to 5.6 months in 
the chemotherapy arm (HR 0.54, p<0.0001) with an ORR of 
62.6% (n=219) with talazoparib (including 12 CRs) compared 
to 27.2% (n=144; no CRs) with chemotherapy. Although grade 
3/4 myelosuppressive toxicities were higher with talazoparib 
than chemotherapy (55 versus 39%), patients experienced 
fewer grade 3/4 gastrointestinal side-effects (5.6 versus 11.9%) 
and had a much slower decline in overall health (as assessed 
by the questionnaire EORTC QLQ-C30) compared to the 
chemotherapy arm.113,114 The Food and Drug Administration 
(FDA) granted priority review designation for talazoparib based 
on the results of EMBRACA.
Niraparib
In the phase I trial NCT00749502 evaluating niraparib in 
patients with advanced malignancies, the ORR was 2 of 4 
gBRCA1/2+ breast cancer patients with one achieving PR at 150 
mg/day for 132 days and the second with PR at 210 mg/day for 
133 days. The RP2D was declared at 300 mg p.o. daily.26 The 
BRAVO study (NCT01905592) is a randomized phase III clinical 
trial investigating niraparib, 300 mg p.o. daily, compared to 
physician’s choice of chemotherapy with a primary outcome 
measure of PFS.
Rucaparib
Rucaparib has been predominantly studied in ovarian cancer, 
but the phase II ‘RUBY’ trial (NCT02505048) is currently recruiting 
patients with metastatic gBRCA-wt, HER2-negative breast 
cancers with a ‘BRCAness’ phenotype as determined by Clovis 
genomic signature testing or BRCA1/2 somatic mutation.115
Veliparib
Veliparib was studied in cancers associated with gBRCA1/2+, 
ovarian cancers, or basal-like HER2-negative breast cancers 
in NCT0089736.31,116 Of the 52 BRCA+ patients (13 with breast 
cancer) evaluated for response (all dose levels included), the 
ORR was 23%, and the CBR was 58%. At the MTD of 400 mg 
p.o. b.i.d., 28 gBRCA1/2+ patients were evaluated with an ORR 
of 40% and CBR 68%. Twenty-four BRCA-wt patients (21 breast 
and 3 ovarian) had an ORR of 4% and CBR of 38%.32 
Combination strategies
Chemotherapy
Recommended monotherapy dosages of PARP inhibitors are 
as follows: niraparib, 300 mg p.o. daily,26 olaparib, 300 mg p.o. 
b.i.d.,28 rucaparib, 600 mg p.o. b.i.d.,117 talazoparib, 1 mg p.o. 
daily,35 and veliparib 400 mg p.o. b.i.d.32 Myelosuppression is 
the primary DLT for PARPi, which has made combination of 
PARPi with cytotoxic chemotherapies problematic (see Table 2). 
The majority of phase I clinical trials using chemotherapy–
PARPi combination approaches has understandably prioritized 
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The phase III randomized, placebo-controlled neoadjuvant 
trial BrighTNess (NCT02032277) was developed based on the 
carboplatin + veliparib results of I-SPY 2, and results were 
recently published.128 Women with operable stage II–III TNBC 
were enrolled with stratification by gBRCA1/2 status and 
randomization to one of the three arms: paclitaxel, 80 mg/
m2 weekly + carboplatin AUC6 on day 1 of a 21-day cycle + 
veliparib, 50 mg p.o. b.i.d. continuously (n=316), paclitaxel + 
carboplatin + placebo p.o. b.i.d., or paclitaxel + IV placebo 
+ placebo p.o. b.i.d. All patients received AC ×4 cycles in the 
adjuvant setting. The primary outcome was pCR. The pCR for 
the triple combination therapy was 53% (168/316), paclitaxel + 
carboplatin yielded a pCR of 58% (92/160), and paclitaxel alone 
had a pCR of 31% (49/158). The triplet combination was superior 
to paclitaxel alone (p<0.0001) but equivalent to paclitaxel + 
carboplatin (p=0.36). It should be noted that paclitaxel, 80 
mg/m2, and carboplatin AUC6 are standard full doses, but the 
veliparib dose is 1/8 of the monotherapy dose of veliparib, 
400 mg p.o. b.i.d. The addition of veliparib, 50 mg p.o. b.i.d., to 
paclitaxel and carboplatin did not improve therapeutic benefit, 
though the addition of carboplatin to paclitaxel clearly did. 
The phase II BROCADE trial (NCT01506609) evaluated veliparib 
in gBRCA1/2+ patients with inoperable locally recurrent or 
metastatic HER2-negative breast cancer.129,130 Patients were 
randomized to one of the three arms: (1) paclitaxel, 175 mg/
m2 on day 1 + carboplatin AUC6 on day 1 + veliparib, 120 
mg p.o. b.i.d. on days 1–7 of a 21-day cycle (VCP; n=97), (2) 
paclitaxel, 175 mg/m2 on day 1 + carboplatin AUC6 on day 1 
+ placebo p.o. b.i.d. on days 1–7 of a 21-day cycle (PCP; n=99), 
or (3) temozolomide, 150–200 mg/m2 on days 1–5 + veliparib, 
40 mg p.o. b.i.d. on days 1–7 of a 28-day cycle (VT; n=94). 
Forty percent of the breast cancer patients had TNBC. mPFS 
was 14.1 months (95% CI: 11.5–16.2 months) in the veliparib + 
carboplatin + paclitaxel (VCP) arm compared to 12.3 months 
(95% CI: 9.3–14.5 months) in the placebo + carboplatin + 
paclitaxel (PCP) arm (HR 0.789, 95% CI: 0.536–1.162, p=0.227). 
mPFS in the veliparib + temozolomide (VT) arm was 7.4 months 
(95% CI: 5.9–8.5 months) with a HR 1.858 (95% CI: 1.278–2.702, 
p=0.001) compared to VCP. Although they were unable to 
detect improvements in the primary endpoint of PFS at p<0.05, 
secondary endpoints of ORR and CBR were improved by the 
addition of veliparib to paclitaxel and carboplatin. ORR was 
77.8% (95% CI: 66.4–86.7) with VCP compared to 61.3% (95% CI: 
49.7–71.9) with PCP (p=0.027). Only 28.6% of patients receiving 
VT achieved a partial or CR (PCP versus VT p<0.001). The CBR 
at 18 weeks was 87.0% (95% CI: 78.3–92.4) for PCP, 90.7% (95% 
CI: 82.2–95.2) for VCP, and 73.0% (95% CI: 62.2–81.2) for VT. 
The phase III randomized, placebo-controlled BROCADE 3 trial 
for gBRCA1/2+ breast cancer patients in the advanced setting 
includes paclitaxel, 80 mg/m2 weekly + carboplatin AUC6 on 
day 1 of a 21-day cycle in each of two arms, but the veliparib 
dose is 120 mg p.o. b.i.d. and is only given on days 1–7 of a 28-
day cycle.131 We eagerly await results from this trial.
Olaparib in combination with chemotherapy is being evaluated 
in the neoadjuvant setting in TNBC or gBRCA1/2+ HER2-negative 
tumors in the phase III randomized, placebo-controlled 
PARTNER study (NCT03150576) in combination with weekly 
paclitaxel, 80 mg/m2 weekly + carboplatin AUC5 on day 1 of a 
21-day cycle.81 At 150 mg p.o. b.i.d., the olaparib dose is half of 
the 300 mg p.o. b.i.d. monotherapy dose and is given for 12 days 
of a 21-day cycle starting either 2 days prior to chemotherapy 
administration or 2 days after chemotherapy administration. 
Radiation therapy 
Radiation therapy induces DNA double-strand breaks, which 
are lethal if not repaired. By interfering with DNA repair, 
PARPi could be expected to act as radiosensitizers. Although 
radiosensitization is a common therapeutic approach in the 
definitive management of some cancers, such as squamous cell 
carcinomas of the head and neck, it is an uncommon strategy 
in the treatment of metastatic breast cancers. Nonetheless, 
the combination of PARPi with radiation therapy is intriguing. 
There are three clinical trials in the clinicaltrials.gov database 
involving PARPi and radiation therapy for the treatment of 
breast cancer. RadioPARP (NCT03109080) is recruiting women 
with (1) inoperable advanced disease, (2) residual disease after 
neoadjuvant therapy and surgery, and (3) metastatic TNBC 
for a dose-escalation trial with olaparib.100 NCT02227082 is 
an olaparib dose-escalation trial in women with inoperable 
locally recurrent and/or metastatic breast cancer.101 Phase I 
NCT01477489 with veliparib + radiation therapy also includes 
patients in the adjuvant setting; this trial has been completed, 
but results have not been published.102 
Angiogenesis, heat-shock protein inhibitors, and immune 
checkpoint inhibitors
Angiogenesis inhibitors and immune checkpoint inhibitors 
have thus far not reliably been shown to be of benefit in  
the treatment of breast cancer, and so there are no current  
FDA-approved indications for their use in breast cancer.132  
The combination of angiogenesis inhibitors and/or immune 
checkpoint inhibitors with PARP inhibitors will likely be safe 
due to nonoverlapping toxicities, and it might be expected that 
PARP inhibitors could be used at full monotherapy dosages. 
Biologically, it has been hypothesized that hypoxia induces 
down-regulation of HRR proteins BRCA1 and RAD51 and 
induces a BRCA-like state that could sensitize cells to PARP 
inhibitors.133,134 NCT01116648 is a completed phase I/II clinical 
trial involving women with recurrent ovarian carcinoma (n=20) 
or metastatic TNBC (n=8; 3 gBRCA1/2+, 1 BRCA1/2-wt, 4 unknown 
BRCA1/2 status).85 The MTD was olaparib, 400 mg p.o. b.i.d., 
in combination with small-molecule VEGFR tyrosine kinase 
inhibitor (TKI) cediranib, 30 mg p.o. daily; the RP2D was olaparib, 
200 mg p.o. b.i.d., with cediranib, 30 mg p.o. daily. None of the 
breast cancer patients achieved complete or partial responses by 
RECIST criteria, but it should also be noted that only two breast 
cancer patients were in the highest dose arm with a therapeutic 
dose of olaparib, 400 mg p.o. b.i.d. Three breast patients had SD 
on olaparib, 200 mg p.o. b.i.d., including two gBRCA1/2+ patients 
with progression at 4 and 7 months.135 Three phase I or II clinical 
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as well.144 If this is clinically relevant, perhaps combinations 
of PARP inhibitors with inhibitors of PI3K, AKT, or mTOR are 
meant to enhance clinical benefit and prolong duration 
of response to PARPi. Phase I clinical trial NCT01623349 is 
evaluating olaparib in combination with PI3K inhibitors BKM120 
or BYL719 in patients with metastatic TNBC after failure of 
one or more cytotoxic regimens.95,145 Olaparib, 300 mg p.o. 
b.i.d., in combination with mTOR inhibitor AZD2014 or AKT 
inhibitor AZD5363 is being evaluated in the phase I/II study 
NCT02208375.98,99 
Conclusions
The recent FDA approval of olaparib has been a much-
welcomed expansion of therapeutic options for metastatic 
gBRCA1/2+ breast cancer patients. If PARPi approvals for breast 
cancer are to follow the same path as those for ovarian cancer, 
we are likely to see the approval of additional PARP inhibitors 
in the near future. To date, there is no data demonstrating an 
OS benefit for PARP inhibitors in breast cancer patients, though 
to be fair, none of the studies discussed in this manuscript has 
been powered to detect OS. In the metastatic setting, OS data 
are difficult to interpret, as treatment options are numerous 
and patients are likely to be treated with a series of therapies 
for disease control. The phase III trial OlympiA is powered to 
assess OS in patients with HER2-negative breast cancer with 
gBRCA1/2 mutations treated with olaparib in the adjuvant 
setting; data are expected in 2020.
Active PARPi monotherapy phase I and II trials hint at a 
willingness to explore their use beyond patients with 
deleterious germline BRCA1/2 mutations to cancers with  
defects in homologous recombination repair, either 
germline or acquired, as well as in TNBC. Several academic 
and commercial institutions are developing assays to test 
tumor tissue for a BRCA-like phenotype, loosely defined as 
homologous recombination repair deficiency, and thus to 
expand the number of patients who could be offered PARP 
inhibitors.26,27 
Combination strategies could also potentially expand the 
role of PARP inhibitors beyond cancers with homologous 
recombination repair defects, though it will take time 
to understand how best to use them to full effect while 
minimizing toxicities. The diversity of currently active early 
phase combination clinical trials is a fascinating reflection of a 
rapidly growing understanding of DNA repair, PARP inhibitor 
resistance mechanisms, and cancer biology. In the details 
and designs of the clinical trials discussed herein, there are 
clues that platinum sensitivity predicts response to PARP 
inhibitors, PARP inhibitors may be useful radiosensitizers and 
chemosensitizers, induction of ‘BRCAness’ is being explored 
for therapeutic exploitation, and that intermittent dosing and 
G-CSF support are feasible tactics to mitigate myelosuppressive 
toxicities of PARP inhibitors in the same way as for cytotoxic 
chemotherapies. PARP inhibitors remain a very active area of 
research, to the benefit of our future patients.
trials combining PARP inhibitors with VEGFR TKIs are currently 
recruiting patients with advanced or metastatic TNBC in the 
second-line-or-beyond setting: NCT03075462 (PARP inhibitor 
fluzoparib + VEGFR inhibitor apatinib), NCT02484404 (olaparib 
+ VEGFR inhibitor cediranib), and NCT02498613 (olaparib + 
cediranib).84,86,87 NCT02484404 also includes an arm with 
olaparib + cediranib + PDL1 inhibitor durvalumab. 
Induction of a BRCA-like phenotype is also the rationale 
behind the phase I dose-escalation clinical trial NCT02898207, 
which combines olaparib with heat-shock protein 90 (HSP90) 
inhibitor onalespib for patients with metastatic TNBC.88 HSP90 
is a chaperone protein that facilitates folding and stabilization 
of BRCA1 (among many other proteins).136 Preclinical data 
suggest that stabilization of deleteriously mutated BRCA1 could 
be a mechanism of resistance to platinum agents and PARP 
inhibitors.137
There are several studies combining PARP inhibitors 
with immune checkpoint inhibitors, including phase I/II 
KEYNOTE-162 (NCT02657889) in TNBC with niraparib, 200 
mg p.o. b.i.d. + PD1 inhibitor pembrolizumab and phase I/
II MEDIOLA (NCT02734004) in gBRCA1/2+ HER2-negative 
metastatic breast cancer patients with olaparib, 300 mg 
p.o. b.i.d. + PD-L1 inhibitor durvalumab.89–91,138 Phase II 
NCT02849496 has enrolled gBRCA1/2+ TNBC patients for 
veliparib in combination with PD-L1 inhibitor atezolizumab, 
phase Ib/II JAVELIN PARP MEDLEY (NCT03330405) is recruiting 
patients with gBRCA1/2+ or ATM-deficient breast cancer for 
evaluation of talazoparib + PD-L1 inhibitor avelumab, and 
phase II DORA (NCT03167619) is soon to start recruiting women 
with platinum-sensitive metastatic TNBC with olaparib, 300 mg 
p.o. b.i.d. + durvalumab.92–94 
Intracellular signaling
The intracellular phosphorylation cascades of the Rat sarcoma, 
rapidly accelerated fibrosarcoma, extracellular signal-regulated 
kinases (RAS–RAF–MEK–ERK) and PI3K–AKT–mTOR pathways 
have been implicated in the proliferation, survival, and metastatic 
potential of numerous types of cancer, thus driving development 
of small-molecule inhibitors targeting these pathways.139,140 PI3K, 
AKT, and mTOR inhibitors are of special interest in clinical trials 
for breast cancer in particular, as enhanced signaling through 
the PI3K–AKT–mTOR pathway is thought to represent a major 
mechanism of resistance to therapies targeting the estrogen 
receptor (ER) and human epidermal growth factor receptor 2 
(HER2).141 There are dozens of inhibitors of the PI3K–AKT–mTOR 
pathway in development and a wide array of combination 
clinical trials in early and late stages, though FDA-approved-
indications for treatment of breast cancer with PI3K–AKT–mTOR 
inhibitors has been thus far limited to mTOR inhibitor everolimus 
in combination with exemestane after failure of letrozole or 
anastrozole for advanced hormone-receptor-positive (HR+), 
HER2-negative breast cancer based on BOLERO-2.142,143 
Preclinical data suggest that upregulation of the PI3K–AKT–
mTOR pathway may contribute to PARP inhibitor resistance 
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